The 19 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 190.00, with a high estimate of 250.00 and a low estimate of 93.00. The median estimate represents a +3.18% increase from the last price of 184.14.
The current consensus among 23 polled investment analysts is to Hold stock in Alnylam Pharmaceuticals Inc. This rating has held steady since August, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.54
Reporting Date Nov 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.